Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17962620 | 1.00 | HPGD (0.46) | HPGDLMNATSHRMDM2ACHE | |
| SCHEMBL17962622 | 0.82 | LMNA (0.65) | HPGDLMNAMAPTHTTMEN1 | |
| SCHEMBL17962618 | 0.81 | HPGD (0.49) | HPGDLMNATSHRACHECA12 | |
| SCHEMBL24624435 | 0.80 | LMNA (0.48) | HPGDLMNATSHRCA12MAPT | |
| SCHEMBL17987976 | 0.77 | KMT2A (0.47) | HPGDLMNATSHRMDM2HTT | |
| SCHEMBL17962570 | 0.77 | USP2 (0.48) | HPGDLMNATSHRMAPTMEN1 | |
| SCHEMBL2656736 | 0.75 | HCRTR1 (0.47) | HPGDLMNATSHRACHECA12 | |
| SCHEMBL24624436 | 0.70 | CAPN1 (0.37) | HPGDLMNAMDM2 | |
| SCHEMBL24624434 | 0.69 | MAPT (0.42) | LMNAMAPTHTTMEN1ALDH1A1 | |
| SCHEMBL17962574 | 0.69 | PKM (0.60) | HPGDLMNATSHRMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195451-B2 | Compositions and methods for viral sensitization | Ottawa Hospital Research Institute and University of Ottawa (CA) | 2025-01-14 | — | — | US | disclosed |
| US-20240360115-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2024-10-31 | — | — | US | disclosed |
| US-20220220101-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2022-07-14 | — | — | US | disclosed |
| US-11339146-B2 | Compositions and methods for viral sensitization | Ottawa Hospital Research Institute and University of Ottawa (CA) | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195451-B2 | Compositions and methods for viral sensitization | CD4, CD74, HLA-DRB1 | HPGD 3706/4885LMNA 3288/4885TSHR 4709/4885 |
| US-11339146-B2 | Compositions and methods for viral sensitization | CD4, CD74, HLA-DRB1 | HPGD 3340/4885LMNA 3735/4885TSHR 4658/4885 |
| US-20220220101-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | CD4, CD74, HAVCR2 | HPGD 4356/4885LMNA 3082/4885TSHR 4598/4885 |
| US-20240360115-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | CD4, CD74, HAVCR2 | HPGD 4356/4885LMNA 3082/4885TSHR 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.